Friday, July 10, 2020

Can Proton Pump inhibitors increase the COVID19 risk ?


10th July 2020, Thursday
Can Proton Pump Inhibitors (PPIs) increase the risk of COVID-19 in current scenario? Pinjala R K

 A study researcher Brennan Spiegel, MD, MSHS, is co-Editor in Chief of the American Journal of Gastroenterology, the publication in which the findings were reported on July 7th 2020. This study shows that 6.4% of 53,130 people surveyed nationwide were COVID-19 positive. After adjusting for other factors, Spiegel and colleagues found that those taking PPIs once daily were at about twice the risk for COVID-19 infection, a rate that rose to about fourfold for people who took PPIs twice a day.
See the source image 


What is the usage of Proton pump inhibitors in the world?
PPIs are the most commonly used drugs in the world. About 15 million people in united states use PPIs every year. Studies suggest that as many as 70% of people taking PPIs get no benefit from them. PPIs were first made available in 1989, and till now they are the best in inhibiting gastric acid secretions and have been used mainly to treat gastroesophageal reflux disease, which affects up to 10% of the adult population daily. Examples of other uses for PPIs are peptic ulcer disease, stress ulcer prophylaxis, Helicobacter pylori (H. pylori) eradication, stomach protection in nonsteroidal anti-inflammatory drugs (NSAIDs) chronic use, Zollinger-Ellison syndrome, upper gastrointestinal bleeding, esophagitis, and dyspepsia. Like any other drug, PPIs have known common minor adverse effects like headaches and gastrointestinal upset. However recent studies have potentially linked long term use of PPIs to some systemic severe adverse effects like increased risk of osteoporosis-related fractures, Clostridium difficile infection, malabsorption of vitamins and minerals such as vitamin B12, calcium and iron, dementia, pneumonia, kidney disease, and stroke. Besides that, some local effects of long-term PPIs use include atrophic gastritis due to prolonged acid suppression, hyper gastrinemia, chronic H. pylori infection, and development of gastric polyps which lead to gastric malignancy

No comments: